Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Acquired by State of Wisconsin Investment Board

State of Wisconsin Investment Board raised its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) by 54.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,130 shares of the company’s stock after buying an additional 19,700 shares during the period. State of Wisconsin Investment Board owned about 0.12% of Sutro Biopharma worth $1,043,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of STRO. Meeder Asset Management Inc. increased its position in shares of Sutro Biopharma by 85.5% during the second quarter. Meeder Asset Management Inc. now owns 3,013 shares of the company’s stock worth $56,000 after purchasing an additional 1,389 shares in the last quarter. Royal Bank of Canada boosted its holdings in Sutro Biopharma by 462.3% in the 1st quarter. Royal Bank of Canada now owns 2,716 shares of the company’s stock valued at $62,000 after purchasing an additional 2,233 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Sutro Biopharma by 28.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,400 shares of the company’s stock valued at $63,000 after purchasing an additional 756 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Sutro Biopharma by 44.3% during the 2nd quarter. Legal & General Group Plc now owns 4,921 shares of the company’s stock valued at $92,000 after acquiring an additional 1,511 shares during the period. Finally, HighMark Wealth Management LLC lifted its position in shares of Sutro Biopharma by 325.4% during the 2nd quarter. HighMark Wealth Management LLC now owns 5,466 shares of the company’s stock valued at $102,000 after acquiring an additional 4,181 shares during the period. Institutional investors own 89.34% of the company’s stock.

STRO opened at $18.89 on Thursday. The firm has a market cap of $871.72 million, a price-to-earnings ratio of -10.38 and a beta of 0.76. Sutro Biopharma, Inc. has a fifty-two week low of $11.50 and a fifty-two week high of $28.30. The company’s 50-day moving average price is $19.65 and its 200 day moving average price is $19.36. The company has a quick ratio of 10.63, a current ratio of 10.63 and a debt-to-equity ratio of 0.07.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings data on Sunday, August 8th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.28. Sutro Biopharma had a negative net margin of 114.69% and a negative return on equity of 32.92%. The firm had revenue of $28.05 million for the quarter, compared to analyst estimates of $13.80 million. Research analysts anticipate that Sutro Biopharma, Inc. will post -1.86 earnings per share for the current year.

Several research analysts recently issued reports on the company. Wells Fargo & Company restated a “buy” rating and set a $30.00 price objective on shares of Sutro Biopharma in a research report on Friday, October 1st. HC Wainwright assumed coverage on shares of Sutro Biopharma in a research note on Friday, June 18th. They set a “buy” rating and a $35.00 price objective for the company. Zacks Investment Research cut shares of Sutro Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, July 14th. TheStreet cut shares of Sutro Biopharma from a “c-” rating to a “d+” rating in a research report on Monday, June 28th. Finally, JMP Securities reaffirmed a “buy” rating and set a $28.00 price target on shares of Sutro Biopharma in a research report on Tuesday, June 22nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $28.14.

In other news, insider Nicki Vasquez sold 3,906 shares of the stock in a transaction that occurred on Tuesday, September 28th. The shares were sold at an average price of $18.62, for a total value of $72,729.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.10% of the company’s stock.

Sutro Biopharma Profile

Sutro Biopharma Inc engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Featured Article: What is the operating income formula?

Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STRO).

Institutional Ownership by Quarter for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.